- Home
- GGB vs NUVL Comparison
GGB vs NUVL Comparison
Compare GGB & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGB
- NUVL
- Stock Information
- Founded
- GGB 1901
- NUVL 2017
- Country
- GGB Brazil
- NUVL United States
- Employees
- GGB N/A
- NUVL N/A
- Industry
- GGB Steel/Iron Ore
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- GGB Industrials
- NUVL Health Care
- Exchange
- GGB Nasdaq
- NUVL Nasdaq
- Market Cap
- GGB 6.2B
- NUVL 5.5B
- IPO Year
- GGB 1999
- NUVL 2021
- Fundamental
- Price
- GGB $2.83
- NUVL $79.49
- Analyst Decision
- GGB Strong Buy
- NUVL Strong Buy
- Analyst Count
- GGB 2
- NUVL 11
- Target Price
- GGB $5.00
- NUVL $112.36
- AVG Volume (30 Days)
- GGB 9.6M
- NUVL 420.4K
- Earning Date
- GGB 02-19-2025
- NUVL 03-04-2025
- Dividend Yield
- GGB 4.99%
- NUVL N/A
- EPS Growth
- GGB N/A
- NUVL N/A
- EPS
- GGB 0.36
- NUVL N/A
- Revenue
- GGB $10,837,144,685.00
- NUVL N/A
- Revenue This Year
- GGB N/A
- NUVL N/A
- Revenue Next Year
- GGB $6.15
- NUVL N/A
- P/E Ratio
- GGB $7.62
- NUVL N/A
- Revenue Growth
- GGB N/A
- NUVL N/A
- 52 Week Low
- GGB $2.67
- NUVL $61.80
- 52 Week High
- GGB $4.04
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- GGB 40.33
- NUVL 43.83
- Support Level
- GGB $2.95
- NUVL $77.84
- Resistance Level
- GGB $3.08
- NUVL $85.21
- Average True Range (ATR)
- GGB 0.08
- NUVL 3.78
- MACD
- GGB -0.01
- NUVL -0.46
- Stochastic Oscillator
- GGB 5.00
- NUVL 12.08
About GGB Gerdau S.A.
Gerdau SA produces steel and steel products. The company operates in civil construction, agriculture, automotive, iron ore, exports, research and development, and home steel products sectors. It offers products such as nails, rebar, columns, billets, slabs, tribar tutor, mechanical construction bars, reinforced steel locks. The company's geographical segment includes Brazil Operations; North America Operations; South America Operations as well as Special Steel Operations. It derives majority of the revenue from the North America Operations segment.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.